CDK4 and head and neck squamous cell carcinoma: In addition, as the CDK4/6-cyclinD complexes act downstream of several oncogenic pathways activated by mechanisms of resistance to cetuximab treatment, future experiments should determine if the addition of CDK4/6 inhibitors could block or postpone acquired resistance to cetuximab in SCCHN.